Flora

Flora Growth (NASDAQ: FLGC) receives INVIMA Current Good Manufacturing Practices (CGMP) certification for Flora Lab 4, a compound prescription formulation ...

Our mission is to create a world where the benefits of cannabis are accessible to everyone, and we are working toward that goal by becoming a leading importer and exporter of cannabis to meet demand in every corner of the market. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora’s filings with the SEC. The words “believe,” “expect,” “anticipate,” “will,” “could,” “would,” “should,” “may,” “plan,” “estimate,” “intend,” “predict,” “potential,” “continue,” and the negatives of these words and other similar expressions generally identify forward looking statements. Flora is committed to creating sustainable growth in its Pharmaceutical division by utilizing high-quality raw materials sourced from its cannabis cultivation and processing operations in Colombia. Our commitment is to create, master and connect the international cannabis supply chain by setting the standard for world-class cultivation and manufacturing, thoughtful brand development, and rigorous research and development of medical-grade cannabis products that meet the highest standards of quality, safety, and efficacy. This offering comes as a law that went into effect on January 1, 2023, requires all insurance providers in the country to cover the cost of medical cannabis treatments for patients. is a global cannabis company dedicated to bringing the benefits of cannabis to people worldwide. We applaud the Colombian government’s acknowledgment of the power of this plant by requiring all health insurance providers to cover the cost of medical cannabis. “We are very pleased to have received CGMP certification and to bring effective medicinal cannabis treatments to patients in Colombia. Flora Lab 4 will now begin offering its cannabis formulations as well as design, development and manufacturing services for third parties. The team hopes to gather patient-reported pilot-study data to better understand patient responses and outcomes. The inspection certifies the lab as meeting Current Good Manufacturing Practices standards as determined by INVIMA.